Premium Members Get 10% Off and Earn Rewards Find Out More
Calcium Channel Blockers
The drugs named calcium channel blockers (CCBs) were initially termed cal­ cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba­ bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter­ mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).
1006175014
Calcium Channel Blockers
The drugs named calcium channel blockers (CCBs) were initially termed cal­ cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba­ bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter­ mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).
169.99 In Stock
Calcium Channel Blockers

Calcium Channel Blockers

Calcium Channel Blockers

Calcium Channel Blockers

Overview

The drugs named calcium channel blockers (CCBs) were initially termed cal­ cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba­ bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter­ mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2).

Product Details

ISBN-13: 9783764364359
Publisher: Birkhäuser Basel
Publication date: 05/14/2004
Series: Milestones in Drug Therapy
Edition description: 2004
Pages: 262
Product dimensions: 6.10(w) x 9.25(h) x (d)

Table of Contents

Historical perspective: from early steps on calcium research to the identification of calcium antagonist prototypes and of the signaling functions of Ca2+.- Calcium channel blockers and calcium channels.- The action of calcium antagonists on Ca2+ movements in isolated vessels.- The tissue selectivity of calcium antagonists.- Acute haemodynamic effects of calcium channel blockers.- Calcium channels and regulation of vascular tone in hypertension.- Long-term effects of calcium antagonists.- Blood pressure-independent effects of calcium antagonists.- From early clinical studies to randomized controlled clinical trials.- Beyond the cardiovascular system.
From the B&N Reads Blog
Page 1 of

Customer Reviews